NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5555.50 34.50 (0.62%)

52,016 NSE+BSE Volume

NSE 19 Dec, 2025 3:31 PM (IST)

66,424.3

Market Cap

High in industry

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

14 Nov 2025

5555.50

0.62%

Traction across segments scaling margins to newer highs

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).

Alkem Laboratories Ltd. is trading below its 30 day SMA of 5665.6

Alkem Laboratories Ltd.

13 Nov 2025

5555.50

0.62%

Opex from CDMO/Med-tech to constrain margin expansion over the near term

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM Laboratories (ALKEM) delivered better-than-expected revenue/EBITDA/PAT, with a beat of 6%/9%/13% for the quarter. The superior performance was driven by broad-based higher revenue growth and lower-than-expected R&D spend for the quarter.

Alkem Laboratories Ltd. is trading above its 200 day SMA of 5203.0

Alkem Laboratories Ltd.

19 Sep 2025

5555.50

0.62%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

13 Aug 2025

5555.50

0.62%

Strong show; growth outlook improving

Buy: Alkem Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q1FY26 performance exceeded our expectations on all fronts. The outperformance was led by a strong showing in India (up 12%) and improved momentum across US (+8.8%) and other international markets (+9%).

Alkem Laboratories Ltd. is trading below its 30 day SMA of 5665.6

Alkem Laboratories Ltd.

30 May 2025

5555.50

0.62%

Alkem Labs (SELL): FY26 to be as flat as FY25

Sell: Alkem Laboratories Ltd.

BOB Capital Markets Ltd.

Alkem missed our estimates where Sales /EBITDA /PAT were 0.4%/17% and 15%. EBITDA margin was 160 bps lower than estimates

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

08 Feb 2025

5555.50

0.62%

Alkem Labs (SELL): Slower growth in a seasonally strong quarter

Sell: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Domestic sales were 6% below our estimates mainly due to slower recovery in the acute therapies and no price hike in NLEM portfolio

Alkem Laboratories Ltd. is trading below its 30 day SMA of 5665.6

Alkem Laboratories Ltd.

14 Nov 2024

5555.50

0.62%

Alkem Labs (BUY): In-line Q2, margins expected to sustain due to cost efficiencies

Buy: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2 reported in-line numbers, where sales/EBITDA were 4% below our estimates. However, PAT was 1% above our estimate

Alkem Laboratories Ltd. is trading below its 30 day SMA of 5665.6

Alkem Laboratories Ltd.

03 Sep 2024

5555.50

0.62%

Focusing on profitable growth across segments

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.